Innovating Works

Lixoft

Desconocido
IDEA-FAST: Identifying Digital Endpoints to Assess FAtigue Sleep and acTivities in daily living in Neurodegene... LIXOFT SAS participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage Fatigue and sleep disturbances are two common and disabling symptoms that affect patients with neurodegenerative disorders (NDD) and immune-...
2019-12-18 - 2026-04-30 | Financiado
DDMORE: Drug Disease Model Resources LIXOFT SAS participó en un FP6: Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD...
2011-03-01 - 2016-08-31 | Financiado
DDMORE: Drug Disease Model Resources LIXOFT SAS participó en un FP7: Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.